Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bromfenac Sodium Salt Sesquihydrate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Bromfenac sodium sesquihydrate, 120638-55-3, Bromfenac sodium [usan], Bromfenac sodium hydrate, Bromsite, Bromfenac monosodium salt sesquihydrate
    Molecular Formula
    C30H28Br2N2Na2O9
    Molecular Weight
    766.3  g/mol
    InChI Key
    PPOSVVJOVKVBPW-UHFFFAOYSA-L
    FDA UNII
    8ECV571Y37
    Bromfenac Sodium is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory activities. Upon ophthalmic administration, bromfenac binds to and inhibits the activity of cyclooxygenase II (COX II), an enzyme which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins (PG). By inhibiting PG formation, bromfenac is able to inhibit PG-induced inflammation, thereby preventing vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, an increase in vascular permeability and an increase in intraocular pressure (IOP).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    disodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;trihydrate
    2.1.2 InChI
    InChI=1S/2C15H12BrNO3.2Na.3H2O/c2*16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;;;;/h2*1-7H,8,17H2,(H,18,19);;;3*1H2/q;;2*+1;;;/p-2
    2.1.3 InChI Key
    PPOSVVJOVKVBPW-UHFFFAOYSA-L
    2.1.4 Canonical SMILES
    C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].O.O.O.[Na+].[Na+]
    2.2 Other Identifiers
    2.2.1 UNII
    8ECV571Y37
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ahr-10282

    2. Bromfenac

    3. Bromfenac Sodium

    4. Duract

    5. Isv-303

    6. Sodium Bromfenac

    2.3.2 Depositor-Supplied Synonyms

    1. Bromfenac Sodium Sesquihydrate

    2. 120638-55-3

    3. Bromfenac Sodium [usan]

    4. Bromfenac Sodium Hydrate

    5. Bromsite

    6. Bromfenac Monosodium Salt Sesquihydrate

    7. Chebi:59176

    8. Sodium 2-amino-3-(4-bromobenzoyl) Phenylacetate Sesquihydrate

    9. 8ecv571y37

    10. Bromday

    11. Yellox

    12. Ahr-10282b

    13. Bromfenac Sodium Salt Sesquihydrate

    14. Disodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;trihydrate

    15. Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate

    16. Bromfenac Sodium (usan)

    17. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-, Monosodium Salt, Sesquihydrate

    18. Dsstox_cid_24206

    19. Dsstox_rid_80119

    20. Dsstox_gsid_44206

    21. Disodium 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate Trihydrate

    22. Bromfenac Ophthalmic

    23. Cas-120638-55-3

    24. Ncgc00164552-01

    25. Bromfenac Ophthalmic Solution

    26. Unii-8ecv571y37

    27. Prolensa (tn)

    28. Bromday (tn)

    29. Xibrom (tn)

    30. Yellox (tn)

    31. 2-amino-3-(4-bromobenzoyl)benzeneacetic Acid Sodium Salt

    32. Sodium 2-(2-amino-3-(4-bromobenzoyl)-phenyl)acetate Trihydrate

    33. Bromfenac Sodium [vandf]

    34. Chembl3181947

    35. Dtxsid8044206

    36. Bromfenac Monosodium Sesquihydrate

    37. Bromfenac Sodium [mart.]

    38. Bromfenac Sodium Hydrate (jp17)

    39. Tox21_112181

    40. Akos016008745

    41. Bromfenac Sodium [orange Book]

    42. Bromfenac Sodium Hydrate [jan]

    43. Tox21_112181_1

    44. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-, Monosodium Salt, Hydrate (2:3)

    45. Ncgc00263519-01

    46. D03163

    47. E79221

    48. Bromfenac Sodium Sesquihydrate [ema Epar]

    49. Bromfenac Monosodium Salt Sesquihydrate [mi]

    50. Q27126510

    51. Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate Sesquihydrate

    52. Sodium [2-amino-3-(p-bromobenzoyl)phenyl]acetate Sesquihydrate

    53. Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate--water (2/3)

    54. 2-amino-3-(4-bromobenzoyl)benzene-acetic Acid Sodium Salt Sesquihydrate

    55. Sodium (-amino-3-(p-bromobenzoyl)phenyl)acetate Sesquihydrate

    56. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-, Sodium Salt, Hydrate (2:2:3)

    2.4 Create Date
    2006-11-22
    3 Chemical and Physical Properties
    Molecular Weight 766.3 g/mol
    Molecular Formula C30H28Br2N2Na2O9
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count11
    Rotatable Bond Count6
    Exact Mass765.99364 g/mol
    Monoisotopic Mass763.99569 g/mol
    Topological Polar Surface Area169 Ų
    Heavy Atom Count45
    Formal Charge0
    Complexity361
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count7
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of postoperative ocular inflammation following cataract extraction in adults.

    Postoperative ocular inflammation

    Prevention of postoperative pain and inflammation associated with cataract surgery, Treatment of postoperative pain and inflammation associated with cataract surgery

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Inflammatory Agents, Non-Steroidal

    Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

    5.2 ATC Code

    S01BC11